Evotec (OTCMKTS:EVTCY) vs. NexImmune (NASDAQ:NEXI) Head-To-Head Comparison

Institutional and Insider Ownership

9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Evotec has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Profitability

This table compares Evotec and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	20.85%	16.02%	7.81%
NexImmune	N/A	-534.32%	-213.72%

Valuation & Earnings

This table compares Evotec and NexImmune”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$572.16 million	1.71	$7.14 million	$0.41	7.22
NexImmune	N/A	N/A	-$32.34 million	($18.29)	0.00

Evotec has higher revenue and earnings than NexImmune. NexImmune is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Summary

Evotec beats NexImmune on 7 of the 10 factors compared between the two stocks.

About Evotec

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.